Rifampin and cell-mediated immune responses in tuberculosis.
To estimate the potential adverse consequences of rifampin therapy on cell-mediated immunity in tuberculosis, we measured in vitro lymphocyte responses to phytohemagglutinin, concanavalin A, pokeweed mitogen, and in vitro and in vivo responses to purified protein derivative tuberculin. Thirty-seven patients treated with therapeutic combinations containing rifampin were compared with 13 persons who had never received the drug. After initial improvement, responses to phytohemagglutinin became depressed in patients receiving rifampin for periods of 4 to 24 months. No significant changes were noted in lymphocyte responses to concanavalin A or pokeweed mitogen. In vitro and in vivo responses to purified protein derivative tuberculin were not altered. Because a favorable therapeutic outcome was achieved in all subjects, we concluded that rifampin does not have clinically significant immunosuppressive activity.
D000818:Animals; D003208:Concanavalin A / Q000494:pharmacology; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D066298:In Vitro Techniques; D037102:Lectins / Q000494:pharmacology; D008214:Lymphocytes / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D008934:Mitogens / Q000494:pharmacology; D012293:Rifampin / Q000627:therapeutic use*; D014373:Tuberculin / Q000494:pharmacology; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000276:immunology
D037102:Lectins; D008934:Mitogens; D014373:Tuberculin; D003208:Concanavalin A; D012293:Rifampin